Mexo-onco integrates immune cell percentage analysis, circulating tumor cell (CTC) subtyping, and cellular functional assays to deliver a comprehensive evaluation ranging from immune status and CTC profiles to cellular functional responses.
Beyond mapping personal immune conditions and circulating tumor cell subtypes, Mexo-onco analyzes the direct effects of 43 active substances on immune cells and CTCs. Furthermore, by establishing an immune cell-CTC co-culture assay to simulate the tumor microenvironment, it evaluates the activation efficacy of immune checkpoint inhibitors (ICIs) on immune cells. By synthesizing these multifaceted functional datasets, Mexo-onco establishes a complete personalized cellular analysis database for applications in health management, cancer risk tracking, treatment response evaluation, and wellness or therapeutic planning.
Immune Cell Percentage Testing utilizes flow cytometry to analyze the proportions of key immune cell populations—including T cells, B cells, and Natural Killer (NK) cells—to assess the overall state of the immune system, serving as an essential baseline for immune function evaluation and health management.
CTC Subtyping employs proprietary cell expansion technology to culture circulating tumor cells (CTCs) and circulating hybrid cells (CHCs) from blood samples, utilizing flow cytometry to analyze eight major cancer cell types as a reference for cancer risk assessment, disease monitoring, and treatment response tracking.
Active Substance Testing exposes cultured immune cells and circulating tumor cells separately to 43 active substances spanning four major categories: nutrients, natural extracts, cytokines, and growth factors. Through bidirectional functional analysis, it evaluates the impact of each active substance on immune cell activity and circulating tumor cells, establishing personalized functional data to serve as a reference for dietary supplements, nutritional therapy, and personal health planning.
Co-cultures immune cells with CTCs to simulate the in vivo tumor microenvironment, while analyzing the impact of immune checkpoint inhibitors (ICIs) on immune cell activation and anti-tumor responses. This assists in evaluating ICI treatment responses and provides potential directions for therapeutic optimization.
Individuals who value health management and wish to gain early insight into their health status
Evaluates immune cell responses to ICIs, providing reference data for healthcare professionals in treatment planning
Evaluates responsiveness to different ICI drugs and serves as a reference for personalized treatment adjustments
Evaluates cellular responses to active substances used with ICIs, serving as a reference for personalized wellness planning
Collect approximately 60 mL of human peripheral blood at a partner institution. The specimen will be delivered to the laboratory within 24 hours to initiate subsequent cell culture and testing analysis.
Utilize flow cytometry analysis technology to test the proportions of key immune cells, such as T cells, B cells, and NK cells, thereby evaluating individual immune status.
Employ proprietary culture technology to culture and expand immune cells and CTCs for subsequent drug testing.
A total of 43 active substances across four categories are used to evaluate the activity of immune cells and CTCs, respectively. A co-culture model of immune cells and CTCs is used to assess the effects of 14 immunotherapy drugs on CTC activity.
Utilize flow cytometry analysis technology to detect eight cancer-related CTC types and evaluate the potential quantity of CTCs in the body, providing references for early risk assessment and health management.
Integrate and comprehensively analyze all test results to issue an exclusive test report, serving as an important reference for developing personalized treatment plans.
Report Delivered in Approximately 14 Working Days
